CD133 expression in osteosarcoma and derivation of CD133+ cells

Molecular Medicine Reports

Volumn 7, Issue 2, 2013, Pages 577-584

  Li, Ji ^a   Zhong, Xiao Yan ^b   Li, Zong Yu ^a   Cai, Jin Fang ^a   Zou, Lin ^a   Li, Jian Min ^c   Yang, Tao ^d   Liu, Wei ^e  

^a JINAN MILITARY GENERAL HOSPITAL   (China)

^b Eighth People's Hospital of Jinan   (China)

^c SHANDONG UNIVERSITY   (China)

^d Shandong Medical Association   (China)

^e AFFILIATED HOSPITAL OF SHANDONG UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

Cancer stem cell; Multidrug resistance; Osteosarcoma

Indexed keywords

CD133 ANTIGEN; MULTIDRUG RESISTANCE PROTEIN 1; TRANSCRIPTION FACTOR SOX2;

ANTIGEN EXPRESSION; ARTICLE; CANCER CELL CULTURE; CANCER STEM CELL; CARCINOGENESIS; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; CELL DIFFERENTIATION; CELL POPULATION; CELL PROLIFERATION; CELL SUBPOPULATION; CELLULAR DISTRIBUTION; COLONY FORMING CELL; COMPARATIVE STUDY; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; OSTEOSARCOMA; OSTEOSARCOMA CELL;

ANTIGENS, CD; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; GLYCOPROTEINS; HUMANS; INTERPHASE; NEOPLASTIC STEM CELLS; OSTEOSARCOMA; P-GLYCOPROTEIN; PEPTIDES; SOXB1 TRANSCRIPTION FACTORS;

EID: 84873816274     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2012.1231     Document Type: Article

References (33)

1. Reya T, Morrison SJ, Clarke MF and Weissman IL: Stem cells, cancer and cancer stem cells. Nature 414: 105-111, 2001.
2. Huntly BJ and Gilliland DG: Leukaemia stem cells and the evolution of cancer stem cell research. Nat Rev Cancer 5: 311-321, 2005.
3. Marx J: Cancer research. Mutant stem cells may seed cancer. Science 301: 1308-1310, 2003.
4. Al Hajj M, Wicha M S, Benito Hernandez A, et al: Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 100: 3983-3988, 2003.
5. Singh SK, Hawkins C, Clarke ID, et al: Identification of human brain tumour initiating cells. Nature 432: 396-401, 2004.
6. Goodell MA, Brose K, Paradis G, et al: Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J Exp Med 183: 1797-1806, 1996.
7. Meyers PA, Schwartz CL, Krailo M, et al: Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin and high dose methotrexate. J Clin Oncol 23: 2004-2011, 2005.
8. Budak Alpdogan T, Banerjee D and Bertino JR: Hematopoietic stem cell gene therapy with drug resistance genes: an update. Cancer Gene Ther 12: 849-863, 2005.
9. Dean M, Fojo T and Bates S: Tumour stem cells and drug resistance. Nat Rev Cancer 5: 275-284, 2005.
10. Donnenberg VS and Donnenberg AD: Multiple drug resistance in cancer revisited: the cancer stem cell hypothesis. J Clin Pharmacol 45: 872-877, 2005.
11. Gerson SL: Drug resistance gene transfer: Stem cell protection and therapeutic efficacy. Exp Hematol 28: 1315-1324, 2000.
12. Richardson C and Bank A: Preselection of transduced murine hematopoietic stem cell populations leads to increased long term stability and expression of the human multiple drug resistance gene. Blood 86: 2579-2589, 1995.
13. Gibbs CP, Kukekov VG, Reith JD, et al: Stem-like cells in bone sarcomas: implications for tumorigenesis. Neoplasia 7: 967-976, 2005.
14. Yin AH, Miraglia S, Zanjani ED, et al: AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood 90: 5002-5012, 1997.
15. Lee A, Kessler JD, Read TA, et al: Isolation of neural stem cells from the postnatal cerebellum. Nat Neurosci 8: 723-729, 2005.
16. Sagrinati C, Netti GS, Mazzinghi B, et al: Isolation and characterization of multipotent progenitor cells from the Bowman's capsule of adult human kidneys. J Am Soc Nephrol 17: 2443-2456, 2006.
17. Richardson GD, Robson CN, Lang SH, et al: CD133, a novel marker for human prostatic epithelial stem cells. J Cell Sci 117: 3539-3545, 2004.
18. Kordes C, Sawitza I, Müller Marbach A, et al: CD133+ hepatic stellate cells are progenitor cells. Biochem Biophys Res Commun 352: 410-417, 2007.
19. Sugiyama T, Rodriguez RT, McLean GW and Kim SK: Conserved markers of fetal pancreatic epithelium permit prospective isolation of islet progenitor cells by FACS. Proc Natl Acad Sci USA 104: 175-180, 2007.
20. Ito Y, Hamazaki TS, Ohnuma K, et al: Isolation of murine hair inducing cells using the cell surface marker prominin 1/CD133. J Invest Dermatol 127: 1052-1060, 2007.
21. Collins AT, Berry PA, Hyde C, et al: Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 65: 10946-10951, 2005.
22. Yin S, Li J, Hu C, et al: CD133 positive hepatocellular carcinoma cells possess high capacity for tumorigenicity. Int J Cancer 120: 1444-1450, 2007.
23. Hermann PC, Huber SL, Herrler T, et al: Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 1: 313-323, 2007.
24. Eramo A, Lotti F, Sette G, et al: Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ 15: 504-514, 2008.
25. Kim CF, Jackson EL, Woolfenden AE, et al: Identification of bronchioalveolar stem cells in normal lung and lung cancer. Cell 121: 823-835, 2005.
26. Fang D, Nguyen TK, Leishear K, et al: A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res 65: 9328-9337, 2005.
27. Ricci-Vitiani L, Lombardi DG, Pilozzi E, et al: Identification and expansion of human colon cancer initiating cells. Nature 445: 111-115, 2007.
28. Prince ME, Sivanandan R, Kaczorowski A, et al: Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci USA 104: 973-978, 2007.
29. Chambers I and Smith A: Self renewal of teratocarcinoma and embryonic stem cells. Oncogene 23: 7150-7160, 2004.
30. Pan CX, Zhu W and Cheng L: Implications of cancer stem cells in the treatment of cancer. Future Oncol 2: 723-731, 2006.
31. Leslie EM, Deeley RG and Cole SP: Multidrug resistance proteins: role of P glycoprotein, MRP1, MRP2 and BCRP (ABCG2) in tissue defense. Toxicol Appl Pharmacol 204: 216-237, 2005.
32. Dietrich CG, Geier A and Oude Elferink RP: ABC of oral bioavailability: transporters as gatekeepers in the gut. Gut 52: 1788-1795, 2003.
33. Staud F and Pavek P: Breast cancer resistance protein (BCRP/ABCG2). Int J Biochem Cell Biol 37: 720-725, 2005.